Table 1: Studies comparing the efficacy and the metabolic impact of different HAART regimens.

First authorStudy NameN Study DesignF-upResults

Cooper [25]STEAL350Randomized to switch from current NRTI to or FDC in HLA-B adults with plasma HIV viral load 50 .96 wNo significant difference for insulin sensitivity, total cholesterol (TC):HDL cholesterol (HDL-C) ratio, or lactate.
Martinez [26]BICOMBO335Randomized to switch from 3TC-containing triple regimens to or FDC in patients with 200 for at least 6 months48 wOne case of AMI
Substudy 80 pts found no difference in IL-6, hsCRP, IL-10, MCP-1, TNFa, ICAM-1, VCAM-1, selectin, adiponectin, insulin and D-dimer
Sax [27]ACTG 52021858Naïve patients randomized to 4 once-daily antiretroviral regimens: ABC+3TC or TDF+FTC plus efavirenz or ritonavir-boosted atazanavir.96 w ABC+3TC versus TDF+FTC median change in TC: 34 versus 26 mg/dL, ; HDL-C: 9 versus 7 mg/dL, ; triglyceride (TG): 25 versus 3 mg/dL, .
Wamsley [28]GEMINI337Naïve patients randomized to either SQV/r 1000 mg/100 mg twice a day (167) or LPV/r 400 mg/100 mg twice a day (170), plus 48 wNo significant differences in the median change from baseline between arms in plasma lipids except for TG, significantly higher in the LPV/r arm
Eron [29]KLEAN878Naïve patients randomized to either fosamprenavir-ritonavir 700 mg/100 mg twice daily or lopinavir-ritonavir 400 mg/100 mg twice daily, plus ABC/3TC48 wNo significant differences between arms.
Molina [30]CASTLE883Naïve patients randomized to atazanavir/ritonavir 300/100 mg once daily (440) opinavir/ritonavir 400/100 mg twice daily (443) plus 24 mMean changes from baseline in TC, LDL-C, and TG were significantly higher with lopinavir/ritonavir .
Mills [31]ARTEMIS689Naïve patients with HIV-1 RNA at least 5000 copies/ml (stratified by HIV-1 RNA and CD4 cell count) randomized to DRV/r 800/100 mg once daily or LPV/r 800/200 mg total daily dose (twice daily or once daily) plus 96 wDRV/r patients had smaller median increases in TG (0.1 and 0.6 mmol/L, resp., ) and TC (0.6 and 0.9 mmol/L, resp., ) than LPV/r patients